[go: up one dir, main page]

EE200200192A - 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid - Google Patents

5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid

Info

Publication number
EE200200192A
EE200200192A EEP200200192A EEP200200192A EE200200192A EE 200200192 A EE200200192 A EE 200200192A EE P200200192 A EEP200200192 A EE P200200192A EE P200200192 A EEP200200192 A EE P200200192A EE 200200192 A EE200200192 A EE 200200192A
Authority
EE
Estonia
Prior art keywords
heterocyclylsulfonylpyrid
dihydropyrazolo
pyrimidin
ones
substituted
Prior art date
Application number
EEP200200192A
Other languages
English (en)
Inventor
Gordon Barber Christopher
Moira Norfor Allerton Charlotte
Nigel Maw Graham
James Rawson David
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924041.8A external-priority patent/GB9924041D0/en
Priority claimed from GB0018660A external-priority patent/GB0018660D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200200192A publication Critical patent/EE200200192A/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200192A 1999-10-11 2000-10-04 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid EE200200192A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9924041.8A GB9924041D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds
GB0018660A GB0018660D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
PCT/IB2000/001430 WO2001027112A1 (en) 1999-10-11 2000-10-04 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
EE200200192A true EE200200192A (et) 2003-06-16

Family

ID=26244758

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200192A EE200200192A (et) 1999-10-11 2000-10-04 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid

Country Status (34)

Country Link
US (1) US6756373B1 (et)
EP (1) EP1222190A1 (et)
JP (1) JP2003511452A (et)
KR (1) KR20020038941A (et)
CN (1) CN1378547A (et)
AP (1) AP2002002455A0 (et)
AR (1) AR022665A1 (et)
AU (1) AU7547900A (et)
BG (1) BG106568A (et)
BR (1) BR0014695A (et)
CA (1) CA2387353A1 (et)
CO (1) CO5261539A1 (et)
CZ (1) CZ20021151A3 (et)
DZ (1) DZ3218A1 (et)
EA (1) EA200200240A1 (et)
EE (1) EE200200192A (et)
GT (1) GT200000168A (et)
HK (1) HK1049834A1 (et)
HU (1) HUP0203438A3 (et)
IL (1) IL149025A0 (et)
IS (1) IS6288A (et)
MA (1) MA26824A1 (et)
NO (1) NO20021695L (et)
NZ (1) NZ517324A (et)
OA (1) OA12058A (et)
PA (1) PA8504401A1 (et)
PE (1) PE20010736A1 (et)
PL (1) PL357522A1 (et)
SK (1) SK4562002A3 (et)
SV (1) SV2002000192A (et)
TN (1) TNSN00198A1 (et)
TR (1) TR200200954T2 (et)
UY (1) UY26383A1 (et)
WO (1) WO2001027112A1 (et)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
EP1176147A1 (en) * 2000-07-28 2002-01-30 Pfizer Limited Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
US6809200B2 (en) 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
CA2459161A1 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
JP2005529927A (ja) * 2002-05-23 2005-10-06 ファイザー インコーポレイテッド 新規な組み合わせ
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
JP4208512B2 (ja) 2002-07-23 2009-01-14 株式会社クラレ 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
PL377657A1 (pl) 2002-12-13 2006-02-06 Warner-Lambert Company Llc Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
DK1620437T3 (da) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
ATE445402T1 (de) * 2004-03-05 2009-10-15 Nycomed Gmbh Neue verwendung von pde5-hemmern
US7569572B2 (en) 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
EP1863795B1 (en) 2005-03-21 2008-10-29 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
CN101248050B (zh) 2005-06-06 2013-07-17 武田药品工业株式会社 有机化合物
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
AR058071A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas.
CA2634019A1 (en) * 2005-12-20 2007-06-28 Pfizer Products Inc. Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist
KR20090042227A (ko) * 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2008044767A1 (en) * 2006-10-13 2008-04-17 Takeda Pharmaceutical Company Limited Aromatic amine derivative and use thereof
WO2008063505A1 (en) * 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
ES2310144B1 (es) * 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
JP2010540621A (ja) * 2007-10-02 2010-12-24 ドン ア ファーマシューティカル カンパニー リミテッド 良性前立腺肥大症および下部尿路症状の治療または予防用組成物、およびその治療または予防方法
AU2008331833A1 (en) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
WO2009075784A1 (en) 2007-12-06 2009-06-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
CN102223799A (zh) 2008-12-06 2011-10-19 细胞内治疗公司 有机化合物
KR20110098731A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN102232077A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
EP2358204B1 (en) * 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
EP2367429B1 (en) 2008-12-06 2017-06-07 Intra-Cellular Therapies, Inc. Organic compounds
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE-1-HEMMER FOR EYE DRESSING
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 製剤および医薬組成物
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
EP3193878B1 (en) 2014-09-17 2021-01-06 Intra-Cellular Therapies, Inc. 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
HK1243936A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
HK1243935A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
UA125650C2 (uk) 2016-09-09 2022-05-11 Інсайт Корпорейшн Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Novel uses
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
HRP20220833T1 (hr) 2018-02-20 2022-10-28 Incyte Corporation Derivati n-(fenil)-2-(fenil)pirimidin-4-karboksamida i odgovarajući spojevi kao inhibitori hpk1 za liječenje raka
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
TW202028207A (zh) 2018-09-25 2020-08-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
MX2022001562A (es) 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
NZ290952A (en) 1994-08-09 1998-05-27 Eisai Co Ltd Phthalazine derivatives optionally substituted in position-1 by (generally benzyl) amino groups
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) 1995-01-20 2005-11-09 大正製薬株式会社 1H−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体
AU708809B2 (en) 1995-03-10 1999-08-12 Sanofi Pharmaceuticals, Inc. 6-aryl pyrazolo{3,4-d}pyrimidin-4-ones and compositions and methods of use thereof
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
CZ299633B6 (cs) 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ATE247117T1 (de) * 1998-04-20 2003-08-15 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DK1123296T3 (da) 1998-10-23 2003-12-08 Pfizer Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6809200B2 (en) * 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
US6407259B1 (en) * 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20020173502A1 (en) * 2001-03-09 2002-11-21 Allerton Charlotte Moira Norfor Pharmaceutically active compounds
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
WO2003012095A1 (en) 2001-07-28 2003-02-13 Midwest Research Institute Thermal tolerant exoglucanase from acidothermus cellulolyticus

Also Published As

Publication number Publication date
KR20020038941A (ko) 2002-05-24
WO2001027112A1 (en) 2001-04-19
US6756373B1 (en) 2004-06-29
AU7547900A (en) 2001-04-23
HUP0203438A3 (en) 2003-05-28
EA200200240A1 (ru) 2002-10-31
CZ20021151A3 (cs) 2003-03-12
CN1378547A (zh) 2002-11-06
PE20010736A1 (es) 2001-07-19
HK1049834A1 (zh) 2003-05-30
HUP0203438A2 (hu) 2003-01-28
PL357522A1 (en) 2004-07-26
EP1222190A1 (en) 2002-07-17
TNSN00198A1 (fr) 2002-05-30
GT200000168A (es) 2002-04-03
IL149025A0 (en) 2002-11-10
PA8504401A1 (es) 2002-04-25
MA26824A1 (fr) 2004-12-20
BR0014695A (pt) 2002-06-18
UY26383A1 (es) 2001-05-31
JP2003511452A (ja) 2003-03-25
SV2002000192A (es) 2002-07-16
NZ517324A (en) 2003-09-26
AR022665A1 (es) 2002-09-04
TR200200954T2 (tr) 2002-09-23
BG106568A (bg) 2002-12-29
CA2387353A1 (en) 2001-04-19
IS6288A (is) 2002-02-26
NO20021695L (no) 2002-06-07
SK4562002A3 (en) 2003-04-01
NO20021695D0 (no) 2002-04-10
CO5261539A1 (es) 2003-03-31
DZ3218A1 (fr) 2001-04-19
OA12058A (en) 2006-05-03
AP2002002455A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
EE200200192A (et) 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid
DK1235830T3 (da) Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
IL169335A0 (en) PYRAZOLO[3,4,-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
DK1220856T3 (da) Pyrazolo[4,3-d]pyrimidinderivater
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
MXPA03002297A (es) Compuestos de triazol utiles como inhibidores de proteina cinasa.
AU2002253794A1 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
HUP0202713A3 (en) Pteridinones as kinase inhibitors
EE200200405A (et) Pürido[2,3-d]pürimidiin-2,7-diamiinid kui kinaasiinhibiitorid
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
PL355098A1 (en) Imidazole compounds used as phosphodiesterase vii inhibitors
DE50001191D1 (de) Pyrazolo[4, 3-d]pyrimidine
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
SI1226143T1 (en) Imidazopyridine derivatives used as phosphodiesterase vii inhibitors
AU2002317850A1 (en) 1-alkyl 0r 1-cycloalkyltriazolo(4,3-a)quinazolin-5-ones as phosphodiesterase inhibitors
HK1079192A (en) Pyrazolo(3,4-b)pyridine compounds, and their use as phosphodiesterase inhibitors
AU2002317788A1 (en) Imidazotriazines for use as phosphodiesterase inhibitors
ZA200301704B (en) Triazole compounds useful as protein kinase inhibitors.
HK1102440A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors